Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.

Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.

Compound 1 showed promising anticancer activity.

Antizyme slows skin tumor growth by reducing cell growth in mice.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

The combination of encorafenib and binimetinib caused few skin issues.

MK-5108 is safe and shows potential against tumors, especially alone.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

The compound 4c showed strong potential as an anticancer agent.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

The drug combination was safe and showed promise in treating advanced tumors.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.

The treatment combination is effective and generally safe for lung cancer.

Targeting ornithine decarboxylase can help prevent skin cancer.